Scrip is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Reversible Drug Resistance in Tumor Cells

This article was originally published in Start Up

Executive Summary

Cancer patients sometimes respond more than once to treatment with the same agent even after resistance develops, supporting the notion that reversible, non-genetic mechanisms may be at work. A group at Massachusetts General Hospital recently identified such a mechanism in non-small-cell lung cancer and has started to trace its origins. They have linked this phenomenon to HDAC and IGF-1 receptor pathway - already known druggable targets - suggesting the potential for combination therapies that could extend the efficacy of some cancer drugs.

You may also be interested in...



A Groundswell In Epigenetics

Two recent papers looking at very different enzymatic activities illustrate how the study of mutation-based alterations in epigenetic mechanisms, and the multiple complex ways in which these alterations reprogram tumor cells, are rapidly advancing both oncology clinical practice and drug development. One identifies a biomarker that would signal the need for aggressive initial leukemia therapy while the other clarifies the mechanism of a drug target in lymphoma.

A Study in RAF: On-Target Effects Can be Surprisingly Fickle

Two independent research teams have shown that current RAF inchibitors, a class of experimental targeted cancer drugs, may only work well in patients with one particular mutation - in an enzyme called BRAF. In other people, the drugs can actually contribute to the growth of tumors. The findings echo develoments earlier in the decade with EGFr inhibitors, which proved to be harmful to some patients until the mechanism of action was worked out and their use subsequently restricted.

A New but Familiar Drug Target for Treating Memory Impairment

Inhibitors of histone deacetylases have been developed as cancer drugs, with only limited use because of toxicities. Now, a research team has shown that HDAC2 impairs memory and learning, suggesting that inhibitors targeting only that molecule could be used to treat neurodegenerative diseases. Buoyed by these new observations, companies with HDAC inhibitors in hand can screen their libraries specifically for activity against this newly-understood target.

Related Content

Topics

Related Companies

Related Deals

UsernamePublicRestriction

Register

SC091962

Ask The Analyst

Please Note: Click here for more information on the Ask the Analyst service.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel